- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-230X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Biologic treatment of Japanese patients with inflammatory bowel disease ; volume:18 ; number:1 ; day:1 ; month:11 ; year:2018 ; pages:1-8 ; date:12.2018
BMC gastroenterology ; 18, Heft 1 (1.11.2018), 1-8, 12.2018
- Creator
-
Mahlich, Jörg
Matsuoka, Katsuyoshi
Sruamsiri, Rosarin
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12876-018-0892-x
- URN
-
urn:nbn:de:101:1-2018122019382574375160
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:57 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Mahlich, Jörg
- Matsuoka, Katsuyoshi
- Sruamsiri, Rosarin
- SpringerLink (Online service)
Other Objects (12)
Socioeconomic equality in initiation of biologic treatment in Danish patients with inflammatory bowel disease
Fecal Lactoferrin Predicts Primary Nonresponse to Biologic Agents in Inflammatory Bowel Disease
A Retrospective Observational Study of Patterns of Biologic Drug Change in Inflammatory Bowel Disease
Racial or ethnic differences on treatment adherence and persistence among patients with inflammatory bowel diseases initiated with biologic therapies
Treatment strategy changes for inflammatory bowel diseases in biologic era: results from a multicenter cohort in Japan, Far East 1000
New treatment options for inflammatory bowel diseases
Preferences Regarding Shared Decision-Making in Japanese Inflammatory Bowel Disease Patients
Inflammatory bowel disease
Predicting Pre-emptive Discussions of Biologic Treatment: Results from an Openness and Preference Survey of Inflammatory Bowel Disease Patients and Their Prescribers
The epidemiological profile of inflammatory bowel disease patients on biologic therapy at a public hospital in Alagoas
Cellular Mechanisms of Etrolizumab Treatment in Inflammatory Bowel Disease
Unravelling the cellular response to the SARS-COV-2 vaccine in inflammatory bowel disease patients on biologic drugs
Socioeconomic equality in initiation of biologic treatment in Danish patients with inflammatory bowel disease
Fecal Lactoferrin Predicts Primary Nonresponse to Biologic Agents in Inflammatory Bowel Disease
A Retrospective Observational Study of Patterns of Biologic Drug Change in Inflammatory Bowel Disease
Racial or ethnic differences on treatment adherence and persistence among patients with inflammatory bowel diseases initiated with biologic therapies
Treatment strategy changes for inflammatory bowel diseases in biologic era: results from a multicenter cohort in Japan, Far East 1000
New treatment options for inflammatory bowel diseases
Preferences Regarding Shared Decision-Making in Japanese Inflammatory Bowel Disease Patients
Inflammatory bowel disease
Predicting Pre-emptive Discussions of Biologic Treatment: Results from an Openness and Preference Survey of Inflammatory Bowel Disease Patients and Their Prescribers
The epidemiological profile of inflammatory bowel disease patients on biologic therapy at a public hospital in Alagoas
Cellular Mechanisms of Etrolizumab Treatment in Inflammatory Bowel Disease
Unravelling the cellular response to the SARS-COV-2 vaccine in inflammatory bowel disease patients on biologic drugs
Socioeconomic equality in initiation of biologic treatment in Danish patients with inflammatory bowel disease
Fecal Lactoferrin Predicts Primary Nonresponse to Biologic Agents in Inflammatory Bowel Disease
A Retrospective Observational Study of Patterns of Biologic Drug Change in Inflammatory Bowel Disease
Racial or ethnic differences on treatment adherence and persistence among patients with inflammatory bowel diseases initiated with biologic therapies
Treatment strategy changes for inflammatory bowel diseases in biologic era: results from a multicenter cohort in Japan, Far East 1000
New treatment options for inflammatory bowel diseases
Preferences Regarding Shared Decision-Making in Japanese Inflammatory Bowel Disease Patients
Inflammatory bowel disease
Predicting Pre-emptive Discussions of Biologic Treatment: Results from an Openness and Preference Survey of Inflammatory Bowel Disease Patients and Their Prescribers
The epidemiological profile of inflammatory bowel disease patients on biologic therapy at a public hospital in Alagoas
Cellular Mechanisms of Etrolizumab Treatment in Inflammatory Bowel Disease